Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Update

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 9,310,000 shares, an increase of 8.8% from the May 31st total of 8,560,000 shares. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is currently 8.4 days. Approximately 7.4% of the company’s shares are short sold.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now directly owns 109,755 shares in the company, valued at $5,488,847.55. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 40,000 shares of company stock worth $1,858,100 over the last three months. Insiders own 2.70% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several institutional investors have recently modified their holdings of HALO. Rise Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter worth approximately $25,000. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter worth approximately $27,000. Principal Securities Inc. purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $34,000. Fidelis Capital Partners LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter worth approximately $52,000. Finally, First Horizon Advisors Inc. lifted its position in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 293 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 1.0 %

NASDAQ HALO traded down $0.51 on Tuesday, hitting $51.51. 142,923 shares of the stock were exchanged, compared to its average volume of 1,246,441. The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44. Halozyme Therapeutics has a fifty-two week low of $32.83 and a fifty-two week high of $53.22. The company has a market cap of $6.56 billion, a PE ratio of 21.50, a PEG ratio of 0.53 and a beta of 1.27. The company has a 50-day moving average price of $45.57 and a 200-day moving average price of $40.54.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.64 by $0.07. The company had revenue of $195.88 million during the quarter, compared to analysts’ expectations of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. Sell-side analysts anticipate that Halozyme Therapeutics will post 3.66 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a report on Monday, June 24th. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. JMP Securities dropped their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a report on Wednesday, May 8th. Benchmark lifted their price objective on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Finally, Piper Sandler cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $48.00 to $51.00 in a report on Friday, June 7th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $57.25.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.